By Chris Wack

 

Pfizer Inc. saw positive results from two studies that make up the Phase 3 registrational program evaluating ulcerative colitis treatment etrasimod, the company said Tuesday.

Both Phase 3 trials achieved all primary and key secondary endpoints, with etrasimod demonstrating a safety profile consistent with previous studies, the company said.

In the 52-week study, clinical remission was 27% for patients receiving etrasimod compared with 7.4% for patients receiving placebo at week 12, and was 32.1% compared with 6.7% at week 52.

In the 12-week study, clinical remission was achieved among 24.8% of patients receiving etrasimod compared with 15.2% of patients receiving placebo.

The 52-week trial showed statistically significant improvements were attained in all key secondary endpoints. All key secondary endpoints were also met at week 12 in the 12-week trial.

Treatment-emergent adverse events were similar between treatment groups in both trials.

Etrasimod, a once-daily, oral, selective sphingosine 1-phosphate receptor modulator, was developed by Arena Pharmaceuticals, which was recently acquired by Pfizer.

 

Write to Chris Wack at chris.wack@wsj.com

 

(END) Dow Jones Newswires

May 24, 2022 07:26 ET (11:26 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Pfizer (NYSE:PFE)
Historical Stock Chart
From Jun 2022 to Jul 2022 Click Here for more Pfizer Charts.
Pfizer (NYSE:PFE)
Historical Stock Chart
From Jul 2021 to Jul 2022 Click Here for more Pfizer Charts.